JP2021524476A5 - - Google Patents
Info
- Publication number
- JP2021524476A5 JP2021524476A5 JP2020565841A JP2020565841A JP2021524476A5 JP 2021524476 A5 JP2021524476 A5 JP 2021524476A5 JP 2020565841 A JP2020565841 A JP 2020565841A JP 2020565841 A JP2020565841 A JP 2020565841A JP 2021524476 A5 JP2021524476 A5 JP 2021524476A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- nos
- composition according
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024060904A JP2024099549A (ja) | 2018-05-24 | 2024-04-04 | 設計された細菌組成物及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862676236P | 2018-05-24 | 2018-05-24 | |
| US62/676,236 | 2018-05-24 | ||
| PCT/US2019/034069 WO2019227085A1 (en) | 2018-05-24 | 2019-05-24 | Designed bacterial compositions and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024060904A Division JP2024099549A (ja) | 2018-05-24 | 2024-04-04 | 設計された細菌組成物及びその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021524476A JP2021524476A (ja) | 2021-09-13 |
| JP2021524476A5 true JP2021524476A5 (https=) | 2022-06-01 |
Family
ID=68615645
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020565841A Pending JP2021524476A (ja) | 2018-05-24 | 2019-05-24 | 設計された細菌組成物及びその使用 |
| JP2024060904A Pending JP2024099549A (ja) | 2018-05-24 | 2024-04-04 | 設計された細菌組成物及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024060904A Pending JP2024099549A (ja) | 2018-05-24 | 2024-04-04 | 設計された細菌組成物及びその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20210196766A1 (https=) |
| EP (1) | EP3801065A4 (https=) |
| JP (2) | JP2021524476A (https=) |
| KR (1) | KR20210024481A (https=) |
| CN (1) | CN112512342A (https=) |
| AU (1) | AU2019275125A1 (https=) |
| BR (1) | BR112020023933A2 (https=) |
| CA (1) | CA3101184A1 (https=) |
| MX (1) | MX2020012602A (https=) |
| WO (1) | WO2019227085A1 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014145958A2 (en) | 2013-03-15 | 2014-09-18 | Seres Health, Inc. | Network-based microbial compositions and methods |
| CA3226196A1 (en) | 2016-06-14 | 2017-12-21 | Vedanta Biosciences, Inc. | Treatment of clostridium difficile infection |
| CN109563470B (zh) * | 2016-06-14 | 2023-04-07 | 健康生物公司 | 对退行性脑疾病具有预防或治疗效果的agathobaculum属菌株及其应用 |
| EP3668527A1 (en) | 2017-08-14 | 2020-06-24 | Seres Therapeutics, Inc. | Compositions and methods for treating cholestatic disease |
| BR112020008552A2 (pt) * | 2017-10-30 | 2020-12-29 | Seres Therapeutics, Inc. | métodos e composições para tratamento de resistência a antibiótico |
| EP3597202A1 (en) * | 2018-07-20 | 2020-01-22 | Maat Pharma | Fecal microbiota composition, for use in reducing treatment-induced inflammation |
| AU2019321681A1 (en) | 2018-08-17 | 2021-02-25 | Vedanta Biosciences, Inc. | Methods of decreasing dysbiosis and restoring a microbiome |
| JP2022548785A (ja) | 2019-09-24 | 2022-11-21 | プロラクタ バイオサイエンス，インコーポレイテッド | 炎症性疾患及び免疫疾患の治療のための組成物及び方法 |
| WO2021057985A1 (zh) * | 2019-09-27 | 2021-04-01 | 成都中医药大学 | 检测粪钙卫蛋白含量的试剂在制备子宫病变筛查试剂盒中的用途 |
| BR112022010411A2 (pt) * | 2019-11-27 | 2022-08-23 | Seres Therapeutics Inc | Composições bacterianas projetadas e usos das mesmas |
| CA3162387A1 (en) * | 2019-12-20 | 2021-06-24 | Graham J. BRITTON | Compositions and methods for treating inflammatory bowel disease |
| IL271775A (en) * | 2019-12-31 | 2021-06-30 | Biomica Ltd | Microbial consortium and uses thereof |
| WO2021163212A1 (en) | 2020-02-10 | 2021-08-19 | Native Microbials, Inc. | Microbial compositions and methods of use for canine enteropathy and dysbiosis |
| AU2021220620A1 (en) * | 2020-02-12 | 2022-08-18 | Universität Zürich | A bacterial composition for the treatment of cancer |
| CA3175041A1 (en) * | 2020-03-10 | 2021-09-16 | Federation Bio Inc. | Microbial consortia for the treatment of disease |
| GB202007452D0 (en) | 2020-05-19 | 2020-07-01 | Microbiotica Ltd | Threrapeutic bacterial composition |
| EP4152959A4 (en) * | 2020-05-21 | 2024-07-03 | Chan Zuckerberg Biohub, Inc. | HIGH COMPLEXITY SYNTHETIC GUT BACTERIAL COMMUNITIES |
| KR20230088680A (ko) | 2020-08-14 | 2023-06-20 | 프롤랙타 바이오사이언스, 인코포레이티드 | 박테리아 요법에 사용하기 위한 인간 모유 올리고당 조성물 |
| WO2022065957A1 (ko) * | 2020-09-28 | 2022-03-31 | 주식회사 천랩 | 미생물을 포함하는 염증성 질환 진단 또는 치료용 조성물 |
| WO2022159711A1 (en) * | 2021-01-21 | 2022-07-28 | Vedanta Biosciences, Inc. | Compositions and methods for treating hepatic encephalopathy |
| US20240148803A1 (en) * | 2021-02-17 | 2024-05-09 | Seres Therapeutics, Inc. | Use of immunotherapy and microbiome modulation to treat cancer |
| US20240226191A1 (en) * | 2021-05-10 | 2024-07-11 | Microba Ip Pty Ltd | Compositions and methods for treating disease |
| NL2028324B1 (en) * | 2021-05-28 | 2022-12-12 | Caelus Pharmaceuticals B V | Insulin-sensitizing agent and butyrate-producing bacterium |
| CN115806893B (zh) * | 2021-09-13 | 2023-10-20 | 中国科学技术大学 | 普通拟杆菌及其组合物在辅助癌症免疫治疗中的应用 |
| IL312781A (en) * | 2021-11-11 | 2024-07-01 | Microba Ip Pty Ltd | Compositions and methods for treating disease |
| CN114496279B (zh) * | 2022-01-12 | 2022-08-30 | 广州保量医疗科技有限公司 | 菌群移植配型的排序方法、系统、计算机设备及存储介质 |
| CN115852001A (zh) * | 2022-11-23 | 2023-03-28 | 深圳海关动植物检验检疫技术中心 | 一种小麦病原菌检测方法及其应用 |
| GB2627012A (en) * | 2023-02-13 | 2024-08-14 | Acad Medisch Ct | Predictive biomarker of neonatal E.coli mediated sepsis |
| CN117797176B (zh) * | 2024-03-01 | 2024-07-02 | 南京大学 | 双孢梭菌在制备治疗非酒精性脂肪性肝病药物中的应用和一种药物 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004104175A2 (en) * | 2003-05-14 | 2004-12-02 | University Of Georgia Research Foundation, Inc. | Probiotic bacteria and methods |
| US8906668B2 (en) * | 2012-11-23 | 2014-12-09 | Seres Health, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
| WO2014088982A1 (en) * | 2012-12-07 | 2014-06-12 | Albert Einstein College Of Medicine Of Yeshiva University | Gut barrier dysfunction treatment and prevention |
| JP2016509003A (ja) * | 2013-02-04 | 2016-03-24 | セレス セラピューティクス インコーポレイテッド | 組成物および方法 |
| MA41020A (fr) * | 2014-11-25 | 2017-10-03 | Evelo Biosciences Inc | Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome |
| WO2016149687A1 (en) * | 2015-03-18 | 2016-09-22 | Whole Biome, Inc. | Methods and compositions relating to microbial treatment and diagnosis of skin disorders |
| EP3319619A4 (en) * | 2015-07-08 | 2019-01-02 | Seres Therapeutics, Inc. | Methods of treating colitis |
| PL3380108T3 (pl) * | 2015-11-24 | 2023-03-27 | Seres Therapeutics, Inc. | Zaprojektowane kompozycje bakteryjne |
| EP3429604A1 (en) * | 2016-03-14 | 2019-01-23 | Holobiome, Inc. | Modulation of the gut microbiome to treat mental disorders or diseases of the central nervous system |
| WO2017160944A2 (en) * | 2016-03-15 | 2017-09-21 | The Regents Of The University Of Michigan | Compositions and methods for treating and preventing graft versus host disease |
| WO2018053443A1 (en) * | 2016-09-16 | 2018-03-22 | uBiome, Inc. | Method and system for panel characterizations |
| KR102708641B1 (ko) * | 2016-09-27 | 2024-09-24 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 미생물유전체를 조정함으로써 면역 체크포인트 차단 요법을 증강시키는 방법 |
| BR112020008552A2 (pt) * | 2017-10-30 | 2020-12-29 | Seres Therapeutics, Inc. | métodos e composições para tratamento de resistência a antibiótico |
| KR20210100662A (ko) * | 2018-12-05 | 2021-08-17 | 세레스 테라퓨틱스, 인코포레이티드 | 박테리아를 안정화시키는 조성물 그리고 이의 용도 |
-
2019
- 2019-05-24 BR BR112020023933-0A patent/BR112020023933A2/pt not_active Application Discontinuation
- 2019-05-24 MX MX2020012602A patent/MX2020012602A/es unknown
- 2019-05-24 WO PCT/US2019/034069 patent/WO2019227085A1/en not_active Ceased
- 2019-05-24 CA CA3101184A patent/CA3101184A1/en active Pending
- 2019-05-24 AU AU2019275125A patent/AU2019275125A1/en not_active Abandoned
- 2019-05-24 US US17/058,351 patent/US20210196766A1/en not_active Abandoned
- 2019-05-24 EP EP19807289.4A patent/EP3801065A4/en not_active Withdrawn
- 2019-05-24 JP JP2020565841A patent/JP2021524476A/ja active Pending
- 2019-05-24 CN CN201980048698.5A patent/CN112512342A/zh active Pending
- 2019-05-24 KR KR1020207036979A patent/KR20210024481A/ko not_active Ceased
-
2024
- 2024-04-04 JP JP2024060904A patent/JP2024099549A/ja active Pending
-
2025
- 2025-02-05 US US19/046,341 patent/US20250367242A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021524476A5 (https=) | ||
| Chen et al. | Orally administered CLA ameliorates DSS-induced colitis in mice via intestinal barrier improvement, oxidative stress reduction, and inflammatory cytokine and gut microbiota modulation | |
| Li et al. | Bifidobacterium breve protects the intestinal epithelium and mitigates inflammation in colitis via regulating the gut microbiota–cholic acid pathway | |
| Riwes et al. | Microbial metabolites and graft versus host disease | |
| KR102413408B1 (ko) | 장내 미생물 조성에 영향을 미치는 미생물 카로티노이드 | |
| US10105329B2 (en) | Modulation of regulatory T cells via G-coupled protein receptor 43 | |
| JP2017513906A (ja) | 炎症性腸疾患の治療に使用するための局所用組成物 | |
| Basak et al. | Bioactives and their roles in bone metabolism of osteoarthritis: evidence and mechanisms on gut-bone axis | |
| WO2015020943A3 (en) | Digestive enzyme composition suitable for enteral administration | |
| JP2000507938A (ja) | 結腸直腸の化学的保護のためのウルソデオキシコール酸化合物及びｎｓａｉｄの組合せ | |
| IL318963A (en) | Compositions comprising 15-hydroxy-eicosapentaenoic acid and methods of using them | |
| JP2021519763A5 (https=) | ||
| Feng et al. | The effects of traditional Chinese medicine and dietary compounds on digestive cancer immunotherapy and gut microbiota modulation: a review | |
| Kang et al. | Propionate‐producing engineered probiotics ameliorated murine ulcerative colitis by restoring anti‐inflammatory macrophage via the GPR43/HDAC1/IL‐10 axis | |
| Yoon | Nutritional approach as therapeutic manipulation in inflammatory bowel disease | |
| Ye et al. | The role of intestinal flora in anti-tumor antibiotic therapy | |
| JP7700109B2 (ja) | 胃腸の健康組成物 | |
| Chengfeng et al. | Engineered polyphenol-keratin nanocarriers enhance probiotic delivery and ameliorate obese ulcerative colitis | |
| Amrouche et al. | Probiotics and prebiotics intervention in respiratory and digestive infections linked to covid-19 | |
| ES2860823T3 (es) | Prevención y tratamiento de afecciones inflamatorias | |
| JP2022088622A5 (https=) | ||
| Ao et al. | Role of the gut microbiota in the pathogenesis and therapeutic approach to osteoporosis | |
| Yi et al. | Dietary intake of Laminaria japonica suppresses intestinal inflammation in dextran-sulfate-sodium-treated mice by modulating gut microbiota dysbiosis | |
| Xie et al. | Overexpression of SIRT1 alleviates oxidative damage and barrier dysfunction in CPB2 toxin-infected IPEC-J2 cells | |
| Pirola et al. | Efficacy of pollen extract in association with group B vitamins for pain relief in chronic prostatitis/chronic pelvic pain syndrome: A survey of urologists' knowledge about its clinical application |